In multivariate analyses, the hazard ratios for total mortality among those in the lowest (referent) to highest quartiles of serum RA measured at study entry were 1.0, 0.83, 0.74, and 0.56, respectively (P-trend<0.001). For cardiovascular mortality, the comparable hazard ratios were 1.0, 0.76, 0.69, and 0.60 (P-trend<0.001). Furthermore, high RA levels (defined as >median) were associated with lower risk of total mortality (adjusted hazard ratios, 0.68; 95% confidence interval, 0.50-0.85; P=0.001) and cardiovascular mortality (adjusted hazard ratios, 0.62; 95% confidence interval, 0.45-0.78; P<0.001) compared with low RA (defined as ≤median). rodents. 14 Furthermore, all-trans RA treatment was shown to be effective in restoring the cardioprotective oxytocin-natriuretic peptides system and preventing abnormal cardiac remodeling in the ob/ob mice. 15 Our recent study showed that dietary supplementation of RA attenuated the development of atherosclerotic lesions in apolipoprotein E-deficient mice.
R etinoic acid (RA), belongs to the retinoid class of chemical compounds, is a major metabolite of vitamin A (retinol) in the diets. 1 It is synthesized from retinol via 2 enzymatic reactions, involving first reversible oxidation of retinol to retinal, and then a second oxidation to RA. 2 The low-molecular weight of RA makes it highly fat-soluble and easily diffusible across cell membranes. It is currently understood that RA exhibits multiple effects on cell growth, differentiation, and proliferation. 3, 4 In the early development, RA organizes the trunk by providing an instructive signal for posterior neuroectoderm and foregut endoderm and a permissive signal for trunk mesoderm differentiation. At later stages, RA contributes to the development of the eye and other organs. 2 RA serves as a functional ligand for 2 families of nuclear hormone receptors: the RA receptors (RARs, including RARα, RARβ, and RARγ) that bind the abundant form of RA known as all-trans RA; and the retinoid X receptors (such as RXRα, RXRβ, and RXRγ) that bind an isomer known as 9-cis RA. [3] [4] [5] However, 9-cis-RA is normally undetectable except when vitamin A is present in excess. 5 Hence, it may play a pharmacological but not a physiological role as an RXR ligand. After binding with their receptors, RA directly regulated transcription of different kinds of genes controlling cell differentiation, embryonic development, and physiological homeostasis. 6, 7 Recent studies have demonstrated the crucial role of RA in the regulation of cardiac development and prevention of the cardiovascular disease. RA is essential during these early stages of embryogenesis and normal development of the embryo, which is important for proper development of the heart and cardiovascular system. [8] [9] [10] An excess or deficiency of vitamin A or its derivative RA may cause various cardiac malformations. 11, 12 The all-trans RA has been shown to modulate proliferative ability and promote reendothelialization after arterial injury. 13 In addition, RA treatment prevented adverse cardiac remodeling through inhibition of the expression of renin-angiotensin system components in hypertensive rodents.
14 Furthermore, all-trans RA treatment was shown to be effective in restoring the cardioprotective oxytocin-natriuretic peptides system and preventing abnormal cardiac remodeling in the ob/ob mice. 15 Our recent study showed that dietary supplementation of RA attenuated the development of atherosclerotic lesions in apolipoprotein E-deficient mice. 16 The improved effects of RA on cardiovascular diseases were further demonstrated in the in vitro studies that are involved in different types of cardiovascular cells. Activation of retinoid signaling effectively enhanced cholesterol efflux from cholesterol-loaded macrophage foam cells. [16] [17] [18] RA treatment inhibited the secretion of coagulatory factors from endothelial cells under proinflammatory conditions. 19 Thus, retinoid therapy may have important implications in limiting or regressing atherosclerotic cardiovascular disease.
Although animal studies provided the appealing data that RA supplementation might be a promising therapeutic nutrient for cardiovascular disease, the clinical relevance of circulating RA in the cardiovascular disease have not been carefully investigated before. Therefore, in this study, we prospectively evaluated the relationship of serum RA with the risk of mortality in patients with coronary artery disease (CAD).
Methods

Study Subjects
Study participants were recruited between October 2008 and December 2011 as part of the Expanded Guangdong Coronary Artery Disease Cohort (EGCADC). [20] [21] [22] [23] EGCADC consisted of patients aged from 40 to 80 years old recruited from GCADC and outpatients from Guangdong General Hospital following the same inclusion and exclusion criteria, ascertainment of CAD, questionnaires and study protocol. A total of 2523 CAD patients were included in the EGCADC (1513 from GCADC and another 1010 from Guangdong General Hospital). The patients will be enrolled if they met one of the following inclusion criteria: history of myocardial infarction (MI), angiographic evidence of >50% stenosis in ≥1 coronary vessels, evidence of exercise-induced ischemia by treadmill or nuclear testing, and history of coronary revascularization or documented diagnosis of CAD by an internist or cardiologist. Participants were excluded if they could not walk 1 block, had MI within the past 6 months, malignancy, with missing or incomplete angiographic data, missing blood samples, laboratory measurements, or the cause of death.
Participants were interviewed to collect information on demographic characteristics, medical history, medication use, behavioral habits, and risk factor prevalence at baseline visit. Smoking was classified as at least 1 cigarette per day and lasting more than half a year. Alcohol drinking was defined as drinking any type of alcoholic beverage at least once a week and lasting beyond 6 months. Medical records were reviewed to confirm history of MI and other conditions and to document previous angiographic findings and previous coronary revascularization. The study was approved by the Institutional Review Board at Sun Yat-sen University. All subjects provided written informed consent at the time of enrollment.
Identification of CAD and Severity Scoring
All coronary angiography was performed in all of the patients with the standard Judkins technique through the femoral artery or brachial artery and scored for luminal narrowing using a modified American Heart Association/American College of Cardiology classification of the coronaries. 24 The angiograms were interpreted by ≥2 independent cardiologists who were blinded to the patients-related profiles of risk factors. Patients with CAD were defined as nonsignificant CAD (visible plaque resulting in >20% but <50% luminal narrowing stenosis) or significant and obstructive CAD (at least 1 major epicardial vessel with >50% luminal narrowing stenosis). 25, 26 Control patients had no evidence of coronary disease at the time of angiography and no history of MI.
Laboratory Measurements
A standardized questionnaire on general information of examination date, birth date, sex, education level, leisure-time physical activity, smoking habits, alcohol consumption, family history of CAD, and medication history were conducted through a face-to-face interview. Smoking was defined as at least 1 cigarette per day and lasting more than half a year. Alcohol drinking was defined as drinking any type of alcoholic beverage at least once a week and lasting 6 months. Smoking and drinking status were classified as never, former, or current. 27 Fasting blood samples were drawn at the baseline visit after an overnight fasting before planned coronary angiography except some emergent patients (<2%). Blood from participants was collected into the appropriate anticoagulant, and plasma was immediately separated by centrifugation and snap frozen. High-density lipoprotein (HDL) cholesterol was measured by colorimetric assay per manufacturer instructions (WAKO Pure Chemical Industries, Osaka, Japan). Apolipoprotein AI and apolipoprotein B were analyzed in plasma by enzyme-linked immunosorbent assay per manufacturer instructions (Alerchek, Portland, OR). Plasma high-sensitivity C-reactive protein (CRP) was measured by high-sensitivity turbidimetric assay (Roche, Basel, Switzerland).
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Measurement of Serum RA
Concentrations of RA in the human serum were measured using a commercially available ELISA kit according to the manufacturer's instructions (Cat. MBS705877; MyBioSource, San Diego, CA). This assay was highly sensitive and specific for the detection of human RA. RA levels were measured in duplicate in serum aliquots that had undergone 1 or 2 freeze-thaw cycles. No significant crossreactivity or interference between human RA and other analogs was observed. This kit has slight cross-reactivity with B12, vitamin H, within 5%, cross-reactivity with vitamin A within 20%. The coefficient of variation for the interassay replicate samples was <8%. 29 We further validated the measurement of serum RA level by using gas chromatography-mass spectrometry method according to the previous report. 30 The duplicate measures of serum RA duplicates across the entire CAD case-control cohort were highly correlated (r=0.86).
Prospective Follow-Up
The median follow-up time is 4.4 years (interquartile range: 3.6-6.1 years). The primary outcome was all-cause mortality. All-cause mortality was confirmed through a combination of hospital medical records, telephone contacts with patients or family members, and death registration at the Guangdong Provincial Center for Disease Control and Prevention. Cardiovascular mortality was defined as death attributable to an ischemic cardiovascular cause (including fatal MI, stroke, and peripheral arterial disease) or sudden death due to an unknown but presumed cardiovascular cause in high-risk patients. MI and revascularization occurring within a month of enrollment were excluded. After excluding the patients lost to follow-up (<1%), based on this EGCADC database, a total of 1499 patients with CAD were deemed eligible for this analysis.
Statistical Analysis
The baseline clinical characteristics are presented as means±SDs or medians with interquartile ranges in cases of continuous data.
Categorical data are shown as number and percentages of total participants. Serum levels of RA are not normally distributed in this cohort and then natural log transformed. Furthermore, to make the effects comparable, the log-transformed variables were standardized to have a mean of 0 and an SD of 1. They were assessed as continuous and categorical traits, initially by per unit log increase and per SD increment and then in third models as a binary variable (high: defined as above median and low: defined as below median). The associations of serum RA with all-cause mortality and cardiovascular mortality were analyzed by Kaplan-Meier curves, as well as Cox proportional hazard regression in models adjusted for age, sex, and then further adjusted for multivariates, including body mass index (BMI, kg/m 2 ), current smoking, presence of diabetes mellitus, hypertension, glomerular filtration rate (L/min), statin use, total cholesterol (mmol/L), HDL (mmol/L), low-density lipoprotein (mmol/L), acute MI or percutaneous coronary intervention or coronary artery bypass graft at enrollment, left ventricular ejection fraction (%), high-sensitivity-CRP at baseline, and Gensini score. Statistical analyses were performed using SPSS 19.0 statistical packages (SPSS Inc, Chicago, IL). A 2-sided P value of <0.05 was regarded as the statistical significance.
Results
Baseline Characteristics of Participants With or Without Mortality
Baseline characteristics of the enrolled 1499 patients with CAD are shown in Table 1 . The average age was 61±11 years of all the participants of whom 65.9% were male, 25% with diabetes mellitus, 52% with hypertension, and 17% were current smokers. Participants who experienced events (all-cause mortality) were largely older patients, with higher prevalence of diabetes mellitus, hypertension, and acute MI; with lower estimated glomerular filtration rate and left ventricular ejection fraction; higher CRP level, more significant CAD burden (higher Gensini score and more obstructive CAD), and also more frequently taking medication, such as angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. In particular, participants with mortality had significantly lower serum RA level than those without mortality.
Association of Serum RA With Demographic and Clinical Characteristics
The bivariate correlation analysis between serum RA and clinical features was shown in Table 2 . Serum RA level was inversely associated with sex, BMI, smoking status, presence of hypertension, diabetes mellitus, and acute MI, left ventricular ejection fraction, estimated glomerular filtration rate, medication usage of statin and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use, high-sensitivity-CRP, and CAD burden (Gensini score) in the univariate analyses. Among these variables, BMI, presence of hypertension and diabetes mellitus, CRP, and Gensini score were still inversely associated with serum RA in the multivariate model.
Association of Serum RA With Adverse Outcomes
During a mean follow-up of 4.4 years (interquartile range: 3.6-6.1 years, representing 4540 person-years of follow-up), the primary outcome of all-cause mortality occurred on 295 participants of which there were 208 subjects with cardiovascular mortality.
Division of the cohort into quartiles according to RA level showed an inverse association of baseline serum RA with all-cause mortality and cardiovascular mortality ( (Table 3) .
Survival analysis further confirmed this inverse association of RA with total mortality and cardiovascular mortality when baseline serum RA level was categorized into the quartiles (Kaplan-Meier, log-rank P<0.001; Figure A and B) .
The baseline serum RA levels were associated with lower risk of future mortality after adjustment for age and sex (logtransformed values, Online Table I ). These associations persisted after further adjustment for all traditional covariates, including high-sensitivity-CRP and Gensini score. We further explored the relationship of RA with total mortality and cardiovascular mortality by using the median to define high or low level of serum RA. Compared with low RA level (≤34 nmol/L), high RA (>34 nmol/L) was associated with lower risk of all-cause mortality in age-and sex-adjusted model (HR, 0.55; 95% CI, 0.39-0.72; P<0.001) and multivariate fully adjusted model (HR, 0.68; 95% CI, 0.50-0.85; P=0.001, Supplemental Table I ). In accordance with this result, high RA was associated with lower risk of the cardiovascular mortality (HR, 0.62; 95% CI, 0.45-0.78; P<0.001) after multivariate adjustment. Survival plot also confirmed a better prognosis for participants with high RA when baseline RA level was categorized into high or low quartiles (Kaplan-Meier, log-rank P<0.001; Online Figure IA and IB).
CAD Subgroup Analyses
There was no significant heterogeneity in the association between the RA and the adverse events based on baseline characteristics. Thus, among patients with obstructive CAD, participants with high RA had an HR of 0.62 (95% CI, 0.47-0.75) compared with an HR of 0.73 (95% CI, 0.59-0.85) for those subjects with nonobstructive CAD.
Discussion
In this study, we demonstrated that lower serum RA level was associated with higher risk of all-cause mortality and cardiovascular mortality in a population-based CAD cohort. These associations persisted after multivariate adjustment for traditional cardiovascular risk factors. Despite these well-known biological cardiovascular protective properties of RA, to our knowledge, this is the first population study to evaluate the relationship of RA, an active metabolite of retinol, with risk of mortality in cardiovascular patients.
Epidemiological evidences indicate that circulating levels of specific vitamins had numerous health benefits and protective effects on the development of cardiovascular diseases. 31, 32 As such, several retinoids and its receptors potentially exert a multifaceted array of beneficial effects in atherosclerotic cardiovascular disease in animal post-balloon injury stenosis in rats studies and atherosclerosis-prone mice. [14] [15] [16] [17] In accordance with this, low plasma retinol, the substrate for the active all-trans RA, is an independent risk factor for coronary events. 33, 34 However, the potential relationship of circulating RA level with mortality risk in patients with CAD was lacking.
In this CAD cohort, we observed that compared with patients without future death, serum RA level were significantly decreased in patients without death during the follow-up. Furthermore, circulating RA level was inversely associated with the traditional cardiovascular risk factors, such as the CRP and Gensini score. In a multivariable logistic regression analysis, participants in the highest quartile of RA compared with that in the lowest quartile of RA had a significantly lower risk of total death (HR, 0.65; 95% CI, 0.49-0.76; P<0.001) after multivariate fully adjusted. More importantly, the risk of cardiovascular death was decreased for 40% in the highest quartile of serum RA versus the lowest quartile (HR, 0.60; 95% CI, 0.44-0.71; P<0.001). In the stratified analyses, the association between the serum RA and the cardiovascular Results are expressed as mean±SD or median (IQR) values and percentage (%) are shown unless stated. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; IQR, interquartile range; LVEF, left ventricular ejection fraction; LDL, low-density lipoprotein; MI, myocardial infarction; PCI, percutaneous coronary intervention; and RA, retinoic acid.
by guest on December 9, 2017 http://circres.ahajournals.org/ Downloaded from mortality was strong not only in subjects with nonobstructive CAD but also still significant even after multivariate adjustment in subjects with obstructive CAD.
Hypothyroidism is documented to be associated with accelerated atherosclerosis and an increased risk of CAD. 35, 36 To avoid the potential impact of this factor on our analysis, subjects with the abnormal thyroid function were excluded from the case-control cohort study. Furthermore, RA has been previously shown to inhibit the secretion and synthesis of thyrotropin in vitro and in vivo. [37] [38] [39] It raises question whether RA may affect thyroid function of the participants included in this study. However, the dose of RA used in the previous studies (up to milligram level) was extremely higher than the circulating RA level in our study (at nanogram level). Thus, we speculate that serum RA could not exert any significant inhibitory effect on thyrotropin secretion and thyroid function in our cohort study.
Two potential reasons that may possibly explain the interaction between the RA quartile and CAD with regard to cardiovascular mortality shall be highlighted: first, as an RAR ligand, all-trans RA treatment may increase cholesterol efflux from foam cells by inducing the expression of ATP-binding cassette G1, which is a key cholesterol transport to mature HDL. In addition, RA level was observed to be positively correlated with HDL concentration in this study. Thus, we speculate that RA may improve the properties of HDL-mediated cholesterol efflux capacity, [15] [16] [17] which has been proved to be strongly and inversely associated with incident cardiovascular events and mortality. 28, [40] [41] [42] Second, RA exhibits potent antiinflammatory and immunomodulatory actions, which may affect angiogenesis and thrombosis. [43] [44] [45] Several limitations of this study merit comment. First, the study subjects were enrolled from hospitals, which may bring about selection bias. In general, inpatients are considered as having a more severe disease status than nonhospitalized patients. However, we included both patients with acute CAD and those with stable manifestation, and some of them were electively admitted patients with mild status. Thus, we can reduce the bias. Second, serum RA concentration was measured only once at baseline of the study cohort. Therefore, we were not able to adjust for possible moderate fluctuations of serum RA during the follow-up, for example, because of increased intake of vitamin A-rich food. Third, we cannot completely exclude the effects of residual confounding resulting from measurement error in the assessment of confounding factors or some unmeasured factors. Finally, the study population is largely nonobese, with a BMI of ≈24. Because metabolism/ levels of RA and retinoid receptors are known to be affected by obesity and the metabolic syndrome, so the data are not fully informative for persons with a high BMI value. Multivariate model indicates the independent determinants of RA using linear regression with the variables in left column entered into the similar model. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; MI, myocardial infarction; and RA, retinoic acid. 
